Biocorrx, Inc. Submits Fast Track Application to FDA for BICX104
- ByInvesting.com
- •
BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders. Its BioCorRx Recovery Program is a non-addictive, medication-assisted treatment (MAT) program for substance abuse that includes peer recovery support. The UnCraveRx Weight Loss Management Program is a medically assisted weight management program that is combined with a virtual platform application. It is also engaged in the research and development of sustained release naltrexone products for the treatment of addiction and other possible disorders. Its products include BICX101, BICX101 and BICX104. Its lead candidate, BICX101, is a sustained-release, injectable naltrexone for the treatment of opioid abuse and alcoholism. It is also developing an implantable naltrexone treatment, BICX104, a long-acting naltrexone implant that can last several months for the treatment of opioid dependence and alcohol use disorders. Its subsidiary is BioCorRx Pharmaceuticals, Inc.